Also, research such as PARAMOUNT, designed as a randomized, parallel-group, double-blind study in a phase II clinical trial of sacubitril/valsartan in the clinical syndrome of HF with preserved ejection fraction (HFpEF), suggested benefits in HFpEF at least in terms of NT-proBNP reduction [228]. The gene discussed is NPPB; the disease is hydrops fetalis.